Paper Review Records
All Paper Review Records
28 valid samples · Newest publication first
Review days = acceptance date − received date. PDF, DOI, and publisher-page sources are retained.
185
days
Subsequent Detection of Clinically Significant Prostate Cancer After Suspicious MRI and an Initial Biopsy Negative for csPCa: A Longitudinal Subgroup Analysis of the MULTIPROS Trial
Authors
Wafa D. Aloufi; Magdalena Szewczyk‐Bieda; Ghulam Nabi; Xinyu Zhang; Yilong Zhang; Cheng Wei; Luigi ManfrediShow moreShow less
Affiliations
1. Division of Imaging Sciences and Technology, School of Medicine University of Dundee, Ninewells Hospital Dundee UK; 2. Department of Radiological Sciences, College of Applied Medical Sciences Taif University Taif Saudi Arabia; 3. Department of Clinical Radiology Ninewells Hospital and Medical School Dundee UK; 4. Division of Population Health and Genomics, School of Medicine University of Dundee Dundee UK; 5. School of Science and Engineering University of Dundee Dundee UK; 6. Division of Respiratory Medicine and Gastroenterology, School of Medicine University of Dundee, Ninewells Hospital Dundee UKShow moreShow less
58
days
Age Does Not Independently Predict Biochemical Recurrence in Prostate Cancer Following Radical Prostatectomy: A Comparative Analysis of 4223 pT2N0R0 Patients
Authors
Mehdi Kardoust Parizi; Pierre I. Karakiewicz; Piotr Chlosta; Peter Nyirády; Tamás Fazekas; Pawel Rajwa; Shahrokh F. ShariatShow moreShow less
Affiliations
1. Department of Urology, Austrian Comprehensive Cancer Center Medical University of Vienna Vienna Austria; 2. Department of Urology, Shariati Hospital Tehran University of Medical Sciences Tehran Iran; 3. Uro‐Oncology Research Center Tehran University of Medical Sciences Tehran Iran; 4. Cancer Prognostics and Health Outcomes Unit, Division of Urology University of Montreal Health Center Montreal Quebec Canada; 5. Department of Urology Jagiellonian University Medical College Kraków Poland; 6. Department of Urology Semmelweis University Budapest Hungary; 7. Second Department of Urology Centre of Postgraduate Medical Education Warsaw Poland; 8. Department of Urology Weill Cornell Medicine New York New York USA; 9. Department of Urology University of Texas Southwestern Dallas Texas USA; 10. College of Medical Health Technologies Al‐Turath University Baghdad Iraq; 11. Hourani Center for Applied Scientific Research Al‐Ahliyya Amman University Amman JordanShow moreShow less
73
days
Real‐World HRR Testing Pathways and Patterns of Detected Alterations in Prostate Cancer From the Multinational ARON‐3 Study
Authors
Lorena Incorvaia; Veronica Mollica; Ondřej Fiala; Kazutoshi Fujita; Yüksel Ürün; Bohuslav Melichar; Javier Molina‐Cerrillo; Teresa Alonso‐Gordoa; Umberto Basso; Maria T. Bourlon; Emmanuel Seront; Ugo De Giorgi; Maria José Juan Fita; Pasquale Rescigno; Tarek Taha; Fernando C. Maluf; Alexandr Poprach; Simona De Summa; Tomas Buchler; Luca Galli; Jindrich Kopecky; Gaetano Aurilio; Jakub Kucharz; Carlo Messina; Gabriel Berlingieri Polho; Sarah Scagliarini; Francesco Grillone; Diogo Assed Bastos; Luigi Formisano; Gian Paolo Spinelli; Alessandra Mosca; Alessandro Rizzo; Aristotelis Bamias; Fernando Sabino Marques Monteiro; Andrey Soares; Francesco Massari; Andrew J. Armstrong; Matteo SantoniShow moreShow less
Affiliations
1. Department of Precision Medicine in Medical Surgical and Critical Care (Me.Pre.C.C.), Section of Medical Oncology, University of Palermo Palermo Italy; 2. Medical Oncology, IRCCS Azienda Ospedaliero‐Universitaria di Bologna Bologna Italy; 3. Department of Oncology and Radiotherapeutics Faculty of Medicine and University Hospital in Pilsen, Charles University Pilsen Czech Republic; 4. Biomedical Center, Faculty of Medicine in Pilsen Charles University Pilsen Czech Republic; 5. ARON Research Foundation ETS Macerata Italy; 6. Department of Urology, Faculty of Medicine Kindai University Kindai Japan; 7. Medical Oncology, Ankara University Medical Faculty Ankara Turkey; 8. Department of Oncology Faculty of Medicine and Dentistry, Palacký University Olomouc Czech Republic; 9. Medical Oncology Department Hospital Universitario Ramón y Cajal Madrid Spain; 10. Oncology 1 Unit, Department of Oncology Istituto Oncologico Veneto IOV IRCCS Padova Italy; 11. Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán Mexico City Mexico; 12. Institut Roi Albert II, Department of Medical Oncology Cliniques Universitaires Saint Luc Brussel Belgium; 13. Department of Medical Oncology IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) “Dino Amadori” Meldola Italy; 14. Medical Oncology, Fundación Instituto Valenciano de Oncología Valencia Spain; 15. Translational and Clinical Research Institute, Centre for Cancer Newcastle University Newcastle upon Tyne UK; 16. Royal Marsden NHS Foundation Trust London UK; 17. Hospital Israelita Albert Einstein São Paulo Brazil; 18. Hospital Beneficência Portuguesa São Paulo Brazil; 19. Masaryk Memorial Cancer Institute, Brno, Czech Republic ‐ Faculty of Medicine Masaryk University Brno Czech Republic; 20. Unità di Diagnostica Molecolare e Farmacogenetica, IRCCS Istituto Tumori Giovanni Paolo II Bari Bari Italy; 21. Department of Oncology Second Faculty of Medicine, Charles University and University Hospital Motol and Homolka Prague Czech Republic; 22. Medical Oncology Unit 2, Azienda Ospedaliera Universitaria Pisana Pisa Italy; 23. Department of Clinical Oncology and Radiotherapy University Hospital Hradec Kralove Hradec Kralove Czech Republic; 24. Division of Cancer Prevention and Genetics, IRCCS European Institute of Oncology Milan Italy; 25. Department of Uro‐Oncology Maria Sklodowska‐Curie National Research Institute of Oncology Warsaw Warsaw Poland; 26. Oncology Unit, A.R.N.A.S. Civico Palermo Italy; 27. Hospital Sirio‐Libanês de São Paulo São Paulo Brazil; 28. Department of Medical Oncology AORN “A. Cardarelli” Naples Italy; 29. Medical Oncology Unit Presidio Ospedaliero Pugliese Ciaccio, Azienda Ospedaliera Universitaria “Renato Dulbecco” Catanzaro Italy; 30. Department of Medicine and Surgery Federico II University Naples Italy; 31. Territorial Oncology Operative Complex Unit ‐ Casa Della Salute di Aprilia ‐ ASL Latina Latina Italy; 32. Oncology Department Candiolo Cancer Institute Torino Italy; 33. Bed Management Presa in Carico, TDM, IRCCS Istituto Tumori “Giovanni Paolo II” Bari Italy; 34. Propaedeutic Department of Internal Medicine, ATTIKON University Hospital, School of Medicine National and Kapodistrian University of Athens Athens Greece; 35. Latin American Cooperative Oncology Group ‐ LACOG Porto Alegre Brazil; 36. Hospital Sírio‐Libanês Brasília Brazil; 37. Department of Medical and Surgical Sciences (DIMEC) University of Bologna Bologna Italy; 38. Duke Cancer Institute Duke University Durham North Carolina USA; 39. Medical Oncology Unit, Macerata Hospital Macerata ItalyShow moreShow less
79
days
Insulin‐Like Growth Factor Axis and Survival in Metastatic Hormone‐Sensitive Prostate Cancer: Post‐Hoc Analysis From the ENZAMET Phase 3 Trial
Authors
Michael A. Cilento; Hui‐Ming Lin; Nicole Yeung; Rachel M.N. Kim; Neil Portman; Martin R. Stockler; Andrew J. Martin; Vinod Subhash; Sonia Yip; Lisa M. Butler; Ian C. Marschner; Peter J. Meikle; Arun A. Azad; Ian D. Davis; Lisa G. Horvath; Christopher J. SweeneyShow moreShow less
Affiliations
1. South Australian Immunogenomics Cancer Institute Adelaide University Adelaide Australia; 2. Department of Medical Oncology Royal Adelaide Hospital Adelaide Australia; 3. Australia and New Zealand Urogenital and Prostate Cancer Trials Group (ANZUP) Sydney Australia; 4. Garvan Institute of Medical Research Sydney Australia; 5. School of Clinical Medicine University of New South Wales Sydney Australia; 6. NHMRC Clinical Trials Centre University of Sydney Camperdown Australia; 7. University of Sydney Camperdown Australia; 8. Department of Medical Oncology Chris O'Brien Lifehouse Sydney Australia; 9. The University of Queensland Brisbane Australia; 10. Baker Heart and Diabetes Institute Melbourne Australia; 11. Department of Cardiovascular Research Translation and Implementation La Trobe University Melbourne Australia; 12. Department of Medical Oncology Peter MacCallum Cancer Centre Melbourne Australia; 13. Sir Peter MacCallum Department of Oncology University of Melbourne Melbourne Australia; 14. Monash University Melbourne Australia; 15. Eastern Health Melbourne AustraliaShow moreShow less
476
days
Years of Life Lost in Incidental Prostate Cancer
Authors
Fabian Falkenbach; Mattia Longoni; Andrea Marmiroli; Quynh Chi Le; Calogero Catanzaro; Michele Nicolazzini; Federico Polverino; Jordan A. Goyal; Riccardo Schiavina; Alessandro Volpe; Gennaro Musi; Felix K. H. Chun; Alberto Briganti; Francesco Montorsi; Fred Saad; Shahrokh F. Shariat; Lars Budäus; Markus Graefen; Pierre I. KarakiewiczShow moreShow less
Affiliations
1. Cancer Prognostics and Health Outcomes Unit, Division of Urology University of Montreal Health Center Montreal Quebec Canada; 2. Martini‐Klinik Prostate Cancer Center University Medical Center Hamburg‐Eppendorf Hamburg Germany; 3. Department of Urology University Hospital Heidelberg Heidelberg Germany; 4. Division of Experimental Oncology/Unit of Urology, URI, Urological Research Institute IRCCS San Raffaele Scientific Institute Milan Italy; 5. Vita‐Salute San Raffaele University Milan Italy; 6. Department of Urology IEO European Institute of Oncology, IRCCS Milan Italy; 7. Department of Oncology and Haemato‐Oncology Università degli Studi di Milano Milan Italy; 8. Department of Urology, Goethe University Frankfurt University Hospital Frankfurt am Main Germany; 9. Department of Urology University of Bologna, St. Orsola‐Malpighi Hospital Bologna Italy; 10. Department of Translational Medicine, Division of Urology, University of Eastern Piedmont Maggiore della Carità Hospita Novara Italy; 11. Department of Oncology, Division of Urology University of Turin Orbassano Italy; 12. Department of Neurosciences, Science of Reproduction and Odontostomatology University of Naples Federico II Naples Italy; 13. Department of Urology, Comprehensive Cancer Center Medical University of Vienna Vienna Austria; 14. Department of Urology Weill Cornell Medical College New York New York USA; 15. Department of Urology University of Texas Southwestern Medical Center Dallas Texas USA; 16. Hourani Center for Applied Scientific Research Al‐Ahliyya Amman University Amman Jordan; 17. Department of Urology University Medical Center Hamburg‐Eppendorf Hamburg GermanyShow moreShow less
49
days
Temporal Trends of Metastatic Prostate Cancer in the Prostate‐Specific Membrane Antigen Positron Emission Tomography Era in the United States
Authors
Leonardo Quarta; Maximilian Filzmayer; Michele Petix; Filippo Orlandi; Jordan A. Goyal; Felix K. H. Chun; Matteo Ferro; Salvatore Micali; Shahrokh F. Shariat; Francesco Barletta; Armando Stabile; Giorgio Gandaglia; Francesco Montorsi; Fred Saad; Alberto Briganti; Pierre I. KarakiewiczShow moreShow less
Affiliations
1. Cancer Prognostics and Health Outcomes Unit University of Montréal Health Center, Division of Urology Montréal Québec Canada; 2. Division of Experimental Oncology/Unit of Urology, URI, Urological Research Institute IRCCS San Raffaele Scientific Institute Milan Italy; 3. Vita‐Salute San Raffaele University Milan Italy; 4. Department of Urology, University Hospital Goethe University Frankfurt Frankfurt am Main Germany; 5. Department of Urology ASST Santi Paolo e Carlo Milan Italy; 6. Università degli Studi di Milano Milan Italy; 7. Department of Urology, AOU di Modena University of Modena and Reggio Emilia Modena Italy; 8. Department of Urology, Comprehensive Cancer Center Medical University of Vienna Vienna Austria; 9. Department of Urology Weill Cornell Medical College New York New York USA; 10. Department of Urology University of Texas Southwestern Medical Center Dallas Texas USA; 11. Hourani Center for Applied Scientific Research Al‐Ahliyya Amman University Amman JordanShow moreShow less
Expert Matching · Case Demo
Turn Your Submission Goalsinto a Verifiable Journal Plan
Share your field, deadline, and author profile. CrushSCI uses real review records to suggest a title direction, shortlist journals, and estimate timelines.
